---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010594"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:47:19.698292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical Q1 revenue up 30% to $436k; operating profit turns positive

## Summary
- Revenue of $436,378 (+30% YoY); Vycor Medical division revenue $418,520 (+31%).
- Non-GAAP cash operating profit of $21,619 vs $8,452 in prior year.
- Gross margin 82% (down from 89%) due to validation, shipping costs and sales mix.
- New distribution agreements signed for France and Spain; three VBAS clinical papers published.
- NovaVision division revenue $17,858 (-3% YoY), remains in development stage.

## SEC filing metadata
- accession: 0001641172-25-010594
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/0001641172-25-010594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010594
- JSON: https://secwatch.observer/filing/0001641172-25-010594.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.